Late recurrence risk
ASCO® guidelines recommend 10 years of hormonal therapy for ER-positive breast cancer based on the aTTom and ATLAS studies.2,3 The challenge facing physicians is identifying which patients are at higher risk of distant recurrence after five years of hormone therapy.
The Breast Recurrence Score test may identify patients who are at higher risk of distant recurrence beyond five years and might have greater benefit from extended hormonal therapy.4
- The association between quantitative ER and tamoxifen benefit has been shown in the landmark NSABP B-14 study.1
- The Recurrence Score result was significantly associated with prediction of late distant recurrence (years 5-15) in patients with higher quantitative ER expression (>9.1).4